gastric cancer, compared with advanced gastric cancer. However, cases of highly advanced gastric carcinoma (incurable, unresectable, or inoperable) are still encountered in clinics. In general, curative surgery is believed to be the most desirable treatment for gastric carcinomas at present. Evaluations of clinical outcomes have indicated a poor prognosis for advanced gastric carcinoma patients who underwent macroscopically curative resection [1] [2] [3] , with fewer than 50% of patients surviving for 5 years. This suggests that surgical treatment alone cannot control the growth of microscopic cancer cells, resulting in metastasis or dissemination in vivo through the surgical procedure. On the other hand, beneficial outcomes for gastric carcinoma patients were achieved through the use of adjuvant chemoradiotherapy along with surgical treatment. This was proven by randomized controlled trials carried out by Macdonald et al. [4], and several reports have also suggested the usefulness of chemotherapy against advanced gastric carcinoma [5] [6] [7] [8] .
gastric cancer, compared with advanced gastric cancer. However, cases of highly advanced gastric carcinoma (incurable, unresectable, or inoperable) are still encountered in clinics. In general, curative surgery is believed to be the most desirable treatment for gastric carcinomas at present. Evaluations of clinical outcomes have indicated a poor prognosis for advanced gastric carcinoma patients who underwent macroscopically curative resection [1] [2] [3] , with fewer than 50% of patients surviving for 5 years. This suggests that surgical treatment alone cannot control the growth of microscopic cancer cells, resulting in metastasis or dissemination in vivo through the surgical procedure. On the other hand, beneficial outcomes for gastric carcinoma patients were achieved through the use of adjuvant chemoradiotherapy along with surgical treatment. This was proven by randomized controlled trials carried out by Macdonald et al. [4] , and several reports have also suggested the usefulness of chemotherapy against advanced gastric carcinoma [5] [6] [7] [8] .
There is a newly developed chemotherapy with the agent S-1, consisting of tegafur; gimeracil (5-chloro-2, 4-dihydropyrimidine-as a dihydropyrimidine dehydrogenase inhibitor), which inhibits 5-fluorouracil (5FU) degradation; and oteracil (monopotassium 1, 2, 3, 4-tetrahydro-2, 4-dioxo-1, 3, 5-triazine-6 carboxylateto reduce the gastrointestinal toxicity caused by the phosphorylation of 5FU) [9] [10] [11] . Several clinical trials involving the administration of S-1 alone for the treatment of measurable lesions of gastric carcinoma showed high response rates, of up to approximately 50% [12, 13] , suggesting the possibility of novel effective regimens that would combine this therapy with other agents against gastric carcinoma. Because cisplatin (CDDP) has been clinically utilized with 5FU against gastric carcinoma worldwide, enhancing tumor toxicity [14] [15] [16] , CDDP was chosen as an agent for combined chemotherapy with S-1 against advanced gastric carcinoma. Abstract S-1 has been developed as a new oral anticancer drug, based on the biological modulation of 5-fluorouracil. We report a patient with highly advanced gastric carcinoma who was treated successfully with a new combination chemoradiotherapy using S-1 and cisplatin (CDDP). The patient was a 37-year-old man who was diagnosed with advanced gastric carcinoma (T4N3M0) that had invaded the diaphragm and the paraaortic tissues. Remarkable tumor reduction was observed in the primary tumor and metastatic lymph nodes around the stomach after three cycles of the therapy. Radiological examination before surgery determined that a partial response (PR) had been achieved by the initial therapy. Adverse effects included only a gastrointestinal disorder that was limited to grade 2 when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity, due to myelosuppression. The patient underwent curative surgery, including total gastrectomy, D2 lymph node dissection, and splenectomy, after completion of the radiochemotherapy regimen. No surgical complication was observed. No tumor cells were detected by pathological evaluation of the resected stomach and all the regional lymph nodes, confirming a pathological complete response (CR; grade 3).
Introduction
Improvements in diagnostic and cancer screening techniques in developed countries over the past decade have led to a dramatic increase in the detection of early We report here a patient with highly advanced gastric carcinoma whose histological diagnosis confirmed his classification as showing a complete response (CR; cancer-free) after he received preoperative chemoradiotherapy that included S-1 and CDDP.
Case report

Staging and classification
The definitions of the Japanese Research Society for Gastric Cancer [17] were utilized in staging, radiological evaluation of the effects, and evaluation of histological efficacy. Combination chemotherapy with S-1 and lowdose CDDP (S-1/CDDP) was evaluated. The toxicity of S-1/CDDP was also classified using the Cancer Therapy Evaluation Program, Common Toxicity Criterion, version 2.0 [18] .
Pretreatment diagnosis
A 37-year-old man was admitted with the chief complaint of dyspnea with severe anemia. Physical examination did not indicate a specific problem. The serum hemoglobin level was 7.1 g/dl. The serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 levels were 100.1 U/ml and 4121 U/ml, respectively. Endoscopy of the upper gastrointestinal tract (gastrointestinal fiberscopy; GIF) demonstrated type 3 advanced gastric carcinoma in the cardia and a metastatic lesion in the esophagus (Fig. 1A,B) . A biopsy specimen indicated that this was a poorly differentiated tubular adenocarcinoma. An abdominal computed to-A B C D E Fig. 1 . A Gastrointestinal fiberoscopy (GIF) before chemotherapy showed an invasive tumor with ulceration causing stenosis (arrows). A diagnosis of type 3 advanced gastric carcinoma was made. B,C A metastatic tumor in the esophagus (arrow) was confirmed by pathological analysis to be a poorly differentiated adenocarcinoma, similar to the primary lesion. D GIF after chemotherapy demonstrated a decreased tumor volume and amelioration of the stenotic change (arrow). E GIF after chemotherapy showed disappearance of the esophageal tumor (arrows); no cancer cells were observed by endoscopic biopsy mography (CT) scan showed that the gastric wall was thickened and the gastric tumor and giant lymph nodes around the stomach had invaded the diaphragm and the paraaortic tissues ( Fig. 2A) . The patient was diagnosed with stage IV advanced gastric carcinoma according to the Japanese classification of gastric carcinoma (cT4, cN3, cH0, cP0; c stage IV). The patient decided to undergo preoperative chemotherapy, carried out in an attempt to downstage the disease. This was done with the patient's informed consent in accordance with the advanced gastric carcinoma treatment protocols.
Combination chemotherapy (S-1/CDDP) with radiation
S-1 (Taiho Pharmaceutical, Tokyo, Japan) was prescribed as an orally administered drug, and CDDP was purchased from Nihon Kayaku (Tokyo, Japan). S-1 was administered orally every day, at a dose of 80 mg/m 2 per day, for 2 weeks, and simultaneously, 20 mg/m 2 per day of CDDP was infused on days 1-5, followed by a 2-day interval without CDDP for 2 weeks. Because the patient developed grade 3 leukocytopenia and grade 3 thrombocytopenia 2 weeks after the initiation of the chemotherapy (total dose: S-1, 1680 mg; CDDP, 320 mg, at that time), there was a 5-week interval without any drugs until the patient recovered from the toxicities. CDDP, at a decreased dose of 4 mg/m 2 per day, was started again, with a decreased dose of S-1 (60 mg/m 2 per day), with a 2-week drug-free interval after 3 weeks of drug administration (7 days of S-1 and 5 days of CDDP a week). The total doses of S-1 and CDDP administered before surgery were 6120 mg and 565 mg, respectively.
Radiation therapy (2 Gy/time per day) was added for the same period that CDDP was administered, with the same interval of drugs. The total dose of radiation was 60 Gy (given in 30 occasions). The irradiated area included the cardia of the stomach, and the esophagus in the thorax and abdomen.
Radiological evaluation and toxicities
The patient's response was evaluated after the chemoradiotherapy. GIF showed remarkable tumor regression and scar formation at the ulcerative lesion in the cardia, as well as the disappearance of the metastatic lesion in the esophagus, where no cancer cells were detected by endoscopic biopsy (Fig. 1D,E) . Abdominal CT showed amelioration of the cancer invasion into the diaphragm. The lesions in the gastric regional and paraaortic lymph nodes had also disappeared. Radiological examination showed a partial response (PR) in the stomach and a complete response (CR) in lymph nodes (Fig. 2B) according to World Health Organization (WHO) criteria [19] . The serum CEA and CA19-9 levels were normalized after the therapy, to 4.5 and 20 U/ml, compared with the pretherapy levels of 100.1 U/ml and 4121 U/ml, respectively (Fig. 3) . As for adverse effects, only gastrointestinal disorder was observed, and this was limited to grade 2, when low-dose CDDP was utilized in the regimen, while an initial high dose of CDDP resulted in grade 3 toxicity due to myelosuppression. 
Intraoperative findings
Laparotomy was used to detect a gastric tumor on the lesser curvature of the esophago-cardiac junction (ECJ). Lymph nodes around the lesser curvature of the stomach were swollen, while the paraaortic lymph nodes were not palpable. Cytology of the peritoneal washes was negative. Total gastrectomy, complete D2 lymph node dissection, and splenectomy were performed.
Postoperative histological diagnosis
Tumor pathological classifications and the grading of histological responses to the preoperative chemotherapy were based upon the General rules for the gastric cancer study in surgery and pathology in Japan [17] . Macroscopic ulcer scars were observed in the cardia (Fig. 4A) , and no tumor cells were observed microscopically in any lesion of the primary tumor, in which the wall structure was completely replaced by scar tissues. The patient was thus diagnosed as showing a CR (Fig.  4B ). In the regional lymph nodes, some of which were previously diagnosed with metastatic lesions, areas with strong fibrosis, lymphocytic infiltrations, and foreign body granuloma were observed, and this was also consistent with a diagnosis of CR (Fig. 4C) .
Postoperative course
No postsurgical complications were observed, and the patient is alive without recurrence, 12 months after surgery and 17 months following the initial chemotherapy.
Discussion
Advanced gastric carcinomas that were treated with macroscopic curative surgery showed a 5-year survival rate of less than 50% in Western countries as well as in Japan [1] [2] [3] , suggesting that surgical outcome alone cannot predict or prevent future recurrence or metastasis. We should therefore appreciate the difficulties of controlling "micro-cancer", which is forming or will be forming metastases, resulting in the dissemination of carcinoma cells. The development of additional strategies to be used in conjunction with surgery is urgently needed to overcome "micro-cancer" that is not eliminated by surgery.
The novel anticancer agent S-1, when given alone, showed a high response rate, of approximately 40%-50%, and low toxicity in several clinical studies of gastric cancer [12, 13] . The clinical effects of 5FU are known to be enhanced by combination with CDDP in several kinds of carcinoma [15] . Previously, in a pilot study, we attempted to evaluate a new preoperative combination chemotherapy against highly advanced gastric carcinomas using S-1 and low-dose CDDP, and this resulted in a good response preoperatively in patients with stage IV gastric cancer [20] . In the study, six of ten patients who underwent surgical resection following the chemotherapy showed a pathological response above grade 1b in either the stomach or lymph nodes. Further studies, including randomized controlled studies, will be necessary to evaluate the efficacy of the preoperative chemotherapy.
In the present patient, a comparatively high dose of CDDP with S-1 was administered, with the addition of radiation, which was administered because of the existence of a metastatic tumor in the patient's esophagus. This combined treatment resulted in complete responses in the primary lesion, the lymph nodes, and the metastatic esophageal tumor. Side effects of the therapy included the development of grade 3 myelosuppression, while low-dose CDDP (4 mg/m 2 per day) did not result in such a severe adverse reaction in the patient, suggesting that additional improvements are needed in order to reduce the toxicity while maintaining the potent anticancer effect of the regimen that includes radiation. In our patient, the dose of CDDP was changed because of the severe toxicity caused by 20 mg/m 2 per day of CDDP. While our previous study demonstrated that the dose of 6 mg/m 2 per day of CDDP showed grade 2 toxicity of bone marrow suppression in almost all patients who received it in combination with S-1 [20] , the recommended dose (RD) of CDDP is still under investigation for regimens with radiation, and a phase I/ II study for determining the RD of CDDP in such a regimen is necessary.
In recent years, patients with advanced gastric carcinomas with a CR, determined by radiological examina- tion, in response to several regimens, have been reported frequently. On the other hand, a CR confirmed by histological examination is rarely found in gastric carcinomas, although Iwahashi et al. [16] reported a case of a histological CR obtained by means of an S-1 and CDDP combination. Although we are not sure whether the prognosis, even for these CR patients, is excellent, we hope to demonstrate that the chemoradiotherapy shows potent efficacy as a first-line treatment for highly advanced gastric carcinoma. While we found grade 3 toxic effects produced by the first A B C Fig. 4 . A The surgically resected stomach. There is neither an ulcerated lesion nor a tumor. The upper part of the stomach showed sclerotic changes with fibrosis (arrows). B The histological appearance indicated an effective response to chemotherapy in the residual tumors. No tumor cells were observed in any lesions of the primary tumor (arrows), leading to a complete response (CR) diagnosis. C The histology also indicated a positive chemotherapeutic response in the residual lymph nodes. Strong fibrosis with lymphocytic infiltrations and foreign body granuloma were observed, and this region was also diagnosed as showing CR. B H&E, ϫ100; C H&E, ϫ100 regimen, with 20 mg/m 2 per day of CDDP, the microscopic CR brought about by the regimen might improve the poor prognosis associated with highly advanced gastric carcinoma.
